BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32714857)

  • 1. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced
    Chen F; Chen N; Yu Y; Cui J
    Front Oncol; 2020; 10():904. PubMed ID: 32714857
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
    Chen C; Zhang C; Lin H; Liu Q; Wu L; Zhou C; Zhang J
    Ther Adv Chronic Dis; 2022; 13():20406223221125706. PubMed ID: 36274751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Zhang S; Li S; Liu J; Yang C; Zhang L; Bao H; Cheng Y
    Clin Lung Cancer; 2022 Mar; 23(2):159-169. PubMed ID: 34247986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis.
    Zheng H; Qin X; Zheng Y; Yang X; Tan J; Cai W; He S; Liao H
    Front Pharmacol; 2023; 14():1238579. PubMed ID: 38269283
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
    Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
    Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Dai J; Liu X; Li J; Qu T; Cui Y; Jin S; Zhang E; Guo R
    Thorac Cancer; 2023 Feb; 14(6):535-543. PubMed ID: 36594109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Deng Z; Qin Y; Liu Y; Zhang Y; Lu Y
    Clin Lung Cancer; 2021 Jan; 22(1):e70-e83. PubMed ID: 33067126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
    Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
    Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis.
    Sakharkar P; Kurup S
    Diseases; 2023 Oct; 11(4):. PubMed ID: 37873790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib plus bevacizumab versus erlotinib alone in patients with
    Deng W; Wang K; Jiang Y; Li D; Bao C; Luo J; Liu L; Huang B; Kong J
    BMJ Open; 2022 Aug; 12(8):e062036. PubMed ID: 35985780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis.
    Zhu Y; Liu C; Xu Z; Zou Z; Xie T; Xing P; Wang L; Li J
    Chin Med J (Engl); 2023 Nov; 136(21):2551-2561. PubMed ID: 37160733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
    Sakharkar P; Kurup S; Deb S; Assaad K; Gesinski D; Gayle EJ
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Asian Pac J Cancer Prev; 2012; 13(10):5177-82. PubMed ID: 23244131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
    Hu D; Zhou YY; Ma HB; Tao MM; Huang QZ; Yang ZZ; Zhou Q
    BMC Pulm Med; 2023 Jun; 23(1):207. PubMed ID: 37316870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
    Li R; Li W; Zhang F; Li S
    Eur J Med Res; 2023 Aug; 28(1):302. PubMed ID: 37635242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.